```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable research reagent extensively employed in platelet studies . This Fab fragment primarily targets the glycoprotein IIb/IIIa receptor on blood cells, blocking platelet aggregation . Therefore , it's frequently employed as a method to examine the mechanisms underlying coagulation and to assess the performance of anticoagulant therapies. Distribution is typically limited to academic settings.
```
The Abciximab Compound Research: Utilizing C7E3 and Compound 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently incorporates the monoclonal protein C7E3 and the molecule identified as 143653-53-6. These reagents are instrumental for analyzing abciximab's mechanism of action, evaluating its therapeutic effect in various clinical settings, and understanding potential predictors of patient outcome. Further study leveraging these specific reagents is expected to provide valuable data for enhancing therapeutic strategies involving cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Scientific Avenues with Abciximab 143653-53-6 and C7E3
Recent studies demonstrate that Abciximab (identified as 143653-53-6) presents significant investigative potential, particularly when associated with the antibody fragment. Early reports indicated that this combination may enhance clinical responses in various heart-related contexts. Further investigation is focused on understanding the specific mode of action between Abciximab and C7E3, including study of platelet aggregation and vascular protection.
- Future research endeavors seek to maximize delivery protocols.
- Animal approaches are were employed to more confirm the theories.
- Clinical trials might be required to thoroughly evaluate patient efficacy.
```
Abciximab (C7E3) for Research: Purity and Characteristics (143653-53-6)
Researchers seeking this antibody for laboratory investigations should rigorously evaluate purity and documented parameters . This product is typically supplied as a solid powder and detailed analytical data including identity by HPLC , potency assays, and check here bacterial endotoxin testing must be available. Ensure the source’s CoA outlines acceptable values for related substances and fulfills relevant quality control criteria .
Pharmaceutical-Grade Abciximab Details & Supply
Acquiring analytical-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires detailed consideration of its source . This glycoprotein is commonly utilized in laboratory experiments, particularly those related to platelet aggregation and occlusion. Available sources offer this material in varying volumes, typically ranging from g to substantial commercial quantities . We recommend reviewing the documentation of analysis to verify purity and appropriateness for your specific application . Furthermore , check the stability date before obtaining to maintain optimal efficacy .
- Typical Purity: >95%
- Storage Conditions: -20°C or controlled conditions
- Application : Platelet Aggregation Suppression Studies